Cargando…
Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia
INTRODUCTION: Recent studies found omega-3 fatty acid deficiency in brain cell membranes of schizophrenic patients. Conventional antipsychotics have many adverse reactions. Safety, availability and low price made omega-3 as a potential supplement for treatment of these patients. This study investiga...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Canadian Center of Science and Education
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796520/ https://www.ncbi.nlm.nih.gov/pubmed/25363186 http://dx.doi.org/10.5539/gjhs.v6n7p103 |
_version_ | 1782421794234302464 |
---|---|
author | Jamilian, Hamidreza Solhi, Hasan Jamilian, Mehri |
author_facet | Jamilian, Hamidreza Solhi, Hasan Jamilian, Mehri |
author_sort | Jamilian, Hamidreza |
collection | PubMed |
description | INTRODUCTION: Recent studies found omega-3 fatty acid deficiency in brain cell membranes of schizophrenic patients. Conventional antipsychotics have many adverse reactions. Safety, availability and low price made omega-3 as a potential supplement for treatment of these patients. This study investigated the efficacy of omega-3 fatty acid as add-on treatment in schizophrenia. MATERIAL & METHODS: A randomized, double blind, placebo controlled fixed-dose, add-on clinical trial conducted over 8 weeks. 60 patients with documented schizophrenia randomly divided into two groups: omega-3(1000 mg/day) (n=30) and placebo (n=30). Patients received omega-3 or placebo in addition to their standard antipsychotic treatment. Patient follow up was done using Positive and Negative syndrome Scale (PANSS). Data analyzed using SPSS software v.20. RESULT: At the end of 8 weeks treatment, PANSS score decreased significantly in both groups (p<0.05) in comparison to baseline. Efficacy of omega-3 in decreasing general psychopathologic and total scores was significant in comparison to placebo group from 4 and 6 weeks after onset of treatment, respectively (p<0.05). Totally, omega-3 supplement therapy efficacy in comparison to sole conventional antipsychotics was 0.86 which was not significant (p>0.05). CONCLUSION: We found that supplemental omega-3 might increase efficacy of conventional antipsychotics in decreasing symptoms of schizophrenia. Low price, rare adverse reactions and availability of omega-3 made this substance a potential supplement in improved treatment of schizophrenia. |
format | Online Article Text |
id | pubmed-4796520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Canadian Center of Science and Education |
record_format | MEDLINE/PubMed |
spelling | pubmed-47965202016-04-21 Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia Jamilian, Hamidreza Solhi, Hasan Jamilian, Mehri Glob J Health Sci Articles INTRODUCTION: Recent studies found omega-3 fatty acid deficiency in brain cell membranes of schizophrenic patients. Conventional antipsychotics have many adverse reactions. Safety, availability and low price made omega-3 as a potential supplement for treatment of these patients. This study investigated the efficacy of omega-3 fatty acid as add-on treatment in schizophrenia. MATERIAL & METHODS: A randomized, double blind, placebo controlled fixed-dose, add-on clinical trial conducted over 8 weeks. 60 patients with documented schizophrenia randomly divided into two groups: omega-3(1000 mg/day) (n=30) and placebo (n=30). Patients received omega-3 or placebo in addition to their standard antipsychotic treatment. Patient follow up was done using Positive and Negative syndrome Scale (PANSS). Data analyzed using SPSS software v.20. RESULT: At the end of 8 weeks treatment, PANSS score decreased significantly in both groups (p<0.05) in comparison to baseline. Efficacy of omega-3 in decreasing general psychopathologic and total scores was significant in comparison to placebo group from 4 and 6 weeks after onset of treatment, respectively (p<0.05). Totally, omega-3 supplement therapy efficacy in comparison to sole conventional antipsychotics was 0.86 which was not significant (p>0.05). CONCLUSION: We found that supplemental omega-3 might increase efficacy of conventional antipsychotics in decreasing symptoms of schizophrenia. Low price, rare adverse reactions and availability of omega-3 made this substance a potential supplement in improved treatment of schizophrenia. Canadian Center of Science and Education 2014-12 2014-09-18 /pmc/articles/PMC4796520/ /pubmed/25363186 http://dx.doi.org/10.5539/gjhs.v6n7p103 Text en Copyright: © Canadian Center of Science and Education http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Articles Jamilian, Hamidreza Solhi, Hasan Jamilian, Mehri Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia |
title | Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia |
title_full | Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia |
title_fullStr | Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia |
title_full_unstemmed | Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia |
title_short | Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia |
title_sort | randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796520/ https://www.ncbi.nlm.nih.gov/pubmed/25363186 http://dx.doi.org/10.5539/gjhs.v6n7p103 |
work_keys_str_mv | AT jamilianhamidreza randomizedplacebocontrolledclinicaltrialofomega3assupplementaltreatmentinschizophrenia AT solhihasan randomizedplacebocontrolledclinicaltrialofomega3assupplementaltreatmentinschizophrenia AT jamilianmehri randomizedplacebocontrolledclinicaltrialofomega3assupplementaltreatmentinschizophrenia |